Official Journal of the Italian Society of Orthopaedics and Traumatology
Table 1 The most common drugs available for the treatment of post-menopausal osteoporosis and other skeletal diseases
Category | Drug class | Drug name | Brand names |
|---|---|---|---|
Anti-resorptive | N-bisphosphonates (N-BPs) | Alendronate Risedronate Zoledronate Ibandronate Pamidronate Minodronate | Binosto®, Fosamax®, Fosavance® Actonel®, Actonel Combi® Aclasta® Zometa® Bondronat®, Bonviva®, Iasibon®, Quodixor® Aredia® |
BPs | Clodronate Etidronate | Bonefos®, Clasteon®, Loron® | |
RANKL inhibitor monoclonal antibody | Denosumab | Prolia®, Xgeva® | |
Anabolic | PTH-related anabolic | Teriparatide | Forsteo®, Livogiva®, Movymia®, Osseffyl®, Sondelbay®, TeriparatideTeva®, Terrosa® |
Bone builder | Anti-sclerostin monoclonal antibody | Romosozumab | Evenity® |